Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | GPR39 | O43194 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571766 | 0.82 | PRMT5 (0.44) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL29911325 | 0.81 | USP30 (0.43) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL18571792 | 0.81 | USP30 (0.43) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL18572404 | 0.79 | PRMT5 (0.42) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL20721540 | 0.79 | USP30 (0.41) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL20475561 | 0.79 | USP30 (0.44) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL26571190 | 0.79 | PRMT5 (0.42) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL27188777 | 0.79 | USP30 (0.63) | USP30MEN1KMT2APIM1IDH1 | |
| SCHEMBL23892688 | 0.78 | MEN1 (0.41) | USP30MEN1KMT2APRMT5WDR77 | |
| SCHEMBL20721599 | 0.78 | USP30 (0.43) | USP30MEN1KMT2APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833668-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11993602-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210277009-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210277009-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3833668-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| WO-2020033282-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | USP30 2310/4885MEN1 2728/4885KMT2A 153/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | USP30 1912/4885MEN1 3275/4885KMT2A 151/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | USP30 2916/4885MEN1 2634/4885KMT2A 193/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | USP30 2310/4885MEN1 2728/4885KMT2A 153/4885 |
| US-11993602-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | USP30 1346/4885MEN1 862/4885KMT2A 65/4885 |
| US-20210277009-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | USP30 1346/4885MEN1 862/4885KMT2A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.